Recent Updates
Recently added Catalysts

Merck KGaA

MKGAFFDA catalysts, PDUFA dates & pipeline intelligence
$169.42
▼ -0.23 · -0.14%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full MKGAF financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
Volume
373.00
Value Traded
63.09 K
Short % Float
-

Cash Data

Unlock MKGAF cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
-
Institutions
-

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every MKGAF catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

MKGAF Catalyst Timeline

Dated clinical, regulatory and corporate events for Merck KGaA

Unlock the full MKGAF catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How MKGAF actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-10Pimjetmi (pimicotinib) PDUFA Date ApprovedPDUFA
Unlock 14 more MKGAF historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
23
Drugs Scored
rNPV / MCap
Top Drug
Top 6%
Mid Cap
(rank 44 of 725)
Percentile Rank
Showing 64 of 189 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Enpatoran Small MoleculesNCT07355218Systematic Lupus ErythematosusPhase 3 RECRUITING 202May 25, 2029
M5049 low dose Small MoleculesNCT05540327Systemic Lupus ErythematosusPhase 2 ACTIVE NOT_RECRUITING 406Aug 12, 2028
Precemtabart tocentecan Antibody-Drug Conjugates (ADCs)NCT07549412Metastatic Colorectal CancerPhase 3 RECRUITING 1,020Oct 16, 2029
M9140 Small MoleculesNCT06710132Solid TumorsPhase 1/2 ACTIVE NOT_RECRUITING 196Dec 23, 2027
M9140 Small MoleculesNCT05464030Colorectal CancerPhase 1 ACTIVE NOT_RECRUITING 220Oct 23, 2026
M5542 BiologicsNCT07932795EczemaPhase 1 NOT YET_RECRUITING 56Aug 14, 2028
M7437 Small MoleculesNCT07360314Advanced Solid TumorsPhase 1 RECRUITING 138Mar 28, 2029
M3554 Small MoleculesNCT06641908Advanced Solid TumorPhase 1 RECRUITING 65Apr 16, 2027
M9466 Small MoleculesNCT06421935Advanced Solid TumorPhase 1 ACTIVE NOT_RECRUITING 60Feb 22, 2027
Cladribine Small MoleculesMarketedNCT04695080Advanced Multiple SclerosisApproved ACTIVE NOT_RECRUITING 204Dec 31, 2027
Cladribine Small MoleculesNCT06463587Generalized Myasthenia GravisPhase 3 RECRUITING 264Nov 12, 2030
Mirdametinib Small MoleculesNCT07840612UndisclosedPhase 1 RECRUITING 17Nov 17, 2026
Pimicotinib Small MoleculesNCT07499362Tenosynovial Giant Cell TumorPhase 2 RECRUITING 20Aug 22, 2028
Avelumab BiologicsMarketedNCT03815643Solid TumorApproved ACTIVE NOT_RECRUITING 2,029Nov 24, 2026
Test: Follitropin alfa Small MoleculesMarketedNCT07340827InfertilityApproved RECRUITING 266Sep 30, 2027
Bintrafusp alfa Small MoleculesCompletedNCT05061823Lung CancerPhase 3 COMPLETED 22Mar 21, 2025
M7824 Small MoleculesCompletedNCT03833661Biliary Tract CancerPhase 2 COMPLETED 159Sep 30, 2022
Bintrafusp alfa Small MoleculesCompletedNCT04246489Uterine Cervical NeoplasmsPhase 2 COMPLETED 146Dec 14, 2022
M7824 Small MoleculesCompletedNCT03840915Carcinoma, Non-Small-Cell LungPhase 1/2 COMPLETED 70Jul 29, 2022
M7824 Small MoleculesCompletedNCT04551950Cervical CancerPhase 1 COMPLETED 25Jun 30, 2022
MSB0011359C Small MoleculesCompletedNCT02699515Solid TumorsPhase 1 COMPLETED 714Feb 21, 2022
Enpatoran Small MoleculesNCT05162586Systemic Lupus ErythematosusPhase 3 COMPLETED 1,062Nov 20, 2024
Enpatoran Small MoleculesCompletedNCT06589713Renal ImpairmentPhase 1 COMPLETED 34Apr 13, 2026
cetuximab BiologicsCompletedNCT02383966Carcinoma, Squamous Cell of Head and NeckPhase 3 COMPLETED 243Dec 20, 2021
Tuvusertib Small MoleculesCompletedNCT06433219Ovarian CancerPhase 2 COMPLETED 63Aug 11, 2026
Unlock the MKGAF pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every MKGAF program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every MKGAF trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock MKGAF insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
No insider trades match the selected filters.
Unlock the full MKGAF insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in MKGAF for Q3 2026.
Unlock every fund holding MKGAF
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in MKGAF
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see MKGAF ownership
Insider and institutional ownership, quarter by quarter.

MKGAF Short Interest

Shares sold short, counted twice a month.

-
Short % of Float
of tradable shares sold short
665.0K
Shares Sold Short
+3.4% vs prior count
-
Days to Cover
trading days of normal volume to buy every short share back
450
Avg Daily Volume
the average used for days to cover
Unlock MKGAF short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock MKGAF option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live MKGAF option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock MKGAF options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How MKGAF ranks across every disease it competes in

Competitive Position is a premium feature
See how MKGAF ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

MKGAF News

About Merck KGaA

BIOPHARMAWATCH ELITE
Trade the next MKGAF catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime